| dbo:abstract
|
- BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD). It has demonstrated proof-of-concept clinical efficacy for depression. As of 2017, it is in phase II clinical trials for the treatment of MDD. It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued. (en)
- LY-2940094 adalah antagonis selektif dan poten untuk reseptor nociceptin yang sedang dikembangkan oleh Eli Lilly untuk terapi depresi mayor dan ketergantungan alkohol. Sampai dengan 2014, LY-2940094 sedang menjalani uji klinik fase II untuk kedua indikasi tersebut. Sampai saat ini struktur kimia senyawa ini masih belum dipublikasikan. (in)
|
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:fdaUniiCode
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 4023 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:cl
| |
| dbp:f
| |
| dbp:h
| |
| dbp:iupacName
|
- [2-[4-[methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol (en)
|
| dbp:legalStatus
| |
| dbp:n
| |
| dbp:o
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- NKQHBJNRBKHUQR-UHFFFAOYSA-N (en)
|
| dbp:synonyms
| |
| dbp:unii
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD). It has demonstrated proof-of-concept clinical efficacy for depression. As of 2017, it is in phase II clinical trials for the treatment of MDD. It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued. (en)
- LY-2940094 adalah antagonis selektif dan poten untuk reseptor nociceptin yang sedang dikembangkan oleh Eli Lilly untuk terapi depresi mayor dan ketergantungan alkohol. Sampai dengan 2014, LY-2940094 sedang menjalani uji klinik fase II untuk kedua indikasi tersebut. Sampai saat ini struktur kimia senyawa ini masih belum dipublikasikan. (in)
|
| rdfs:label
|
- BTRX-246040 (en)
- LY-2940094 (in)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |